Financial Ratios

GUFIC BIOSCIENCES LTD.

NSE : GUFICBIOBSE : 509079ISIN CODE : INE742B01025Industry : Pharmaceuticals & DrugsHouse : Private
BSE296.65-10.4 (-3.39 %)
PREV CLOSE ( ) 307.05
OPEN PRICE ( ) 300.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 9584
TODAY'S LOW / HIGH ( )296.00 303.05
52 WK LOW / HIGH ( )192 364
NSE296.55-9 (-2.95 %)
PREV CLOSE( ) 305.55
OPEN PRICE ( ) 305.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 296.55 (148)
VOLUME 157093
TODAY'S LOW / HIGH( ) 295.00 305.40
52 WK LOW / HIGH ( )193.55 364.9
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)8.229.894.562.342.82
   CEPS(Rs)10.5211.846.243.773.42
   DPS(Rs)0.100.100.100.050.05
   Book NAV/Share(Rs)35.8827.7617.8913.349.68
   Tax Rate(%)25.3124.4423.3624.6937.93
Margin Ratios
   Core EBITDA Margin(%)16.8117.4516.1813.3112.76
   EBIT Margin(%)14.3515.5913.7511.2512.63
   Pre Tax Margin(%)13.3314.9611.137.709.81
   PAT Margin (%)9.9511.308.535.806.09
   Cash Profit Margin (%)12.7413.5311.679.347.38
Performance Ratios
   ROA(%)11.5420.9810.005.658.04
   ROE(%)25.8443.3129.2222.1733.89
   ROCE(%)23.2347.2930.0521.0129.65
   Asset Turnover(x)1.161.861.170.981.32
   Sales/Fixed Asset(x)3.765.173.945.1410.57
   Working Capital/Sales(x)4.556.315.3511.677.81
Efficiency Ratios
   Fixed Capital/Sales(x)0.270.190.250.190.09
   Receivable days81.3659.4081.4397.9893.16
   Inventory Days68.1445.1876.30101.0595.44
   Payable days167.52124.89184.25227.30173.92
Valuation Parameters
   PER(x)22.7025.1825.0520.1526.98
   PCE(x)17.7421.0218.3012.5122.26
   Price/Book(x)5.208.976.393.537.86
   Yield(%)0.050.040.090.110.07
   EV/Net Sales(x)3.003.142.361.471.94
   EV/Core EBITDA(x)15.1216.2013.129.6313.60
   EV/EBIT(x)18.0518.5116.1212.6614.99
   EV/CE(x)2.414.692.931.132.20
   M Cap / Sales2.623.102.271.211.69
Growth Ratio
   Net Sales Growth(%)-11.3659.7628.748.0014.79
   Core EBITDA Growth(%)-9.2072.4251.3715.4520.44
   EBIT Growth(%)-13.0685.3062.00-3.2317.19
   PAT Growth(%)-16.84116.6894.963.4133.17
   EPS Growth(%)-16.83116.6794.96-16.9833.17
Financial Stability Ratios
   Total Debt/Equity(x)0.900.230.320.901.30
   Current Ratio(x)1.611.721.591.101.21
   Quick Ratio(x)0.971.101.020.730.78
   Interest Cover(x)13.9824.645.233.174.48
   Total Debt/Mcap(x)0.170.030.060.320.17

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.